|
KMID : 0984920130150020109
|
|
Journal of Skin Barrier Research
2013 Volume.15 No. 2 p.109 ~ p.110
|
|
|
The Effect of Novel Cannabinoid Receptor Agonists on the Oxazolone Induced Atopic Dermatitis Mouse Model
|
|
Kim Hyun-Jung
Jeong Se-Kyoo
Hong Seung-Phil
Lee Seung-Hee
Kim Kkot-Byeol
Jang Mi-Jin
Lee Seon-Ah
Ahn Sung-Gu
|
|
|
Abstract
|
|
|
|
The newly discovered endocannabinoid system(ECS) has been implicated in multiple regulatory functions both in health and disease. Two cannabinoid receptor, CB1 and CB2, is important receptor to be partly ECS. Recent studies have suggested the existence of a functional ECS in the skin and implicated it in various biological processes. The expression of CB1 according to differentiation pattern of normal human keratinocyte was examined in calcium induced2D model and 3D culture model.Modulation of the fine tuned tone of the cutaneous endocanabinoid system could have therapeutic values in the management of a large variety of human skin disease. Endocannabinoids limit excessive mast cell maturation and activation in human skin CB1 receptors are functionally expressed by KCs in vivo and help to limit the secretion of proinflammatory chemokines that regulate T cell.dependent inflammation in the effector phase of CHS. Based on the anti-inflammatory effect and barrier prone effect of CB1 agonist , we tried to check out the possibility of new CB1 agonists for AD treatment using Oxazolone-AD Model. Topical CB1r agonist showed significant anti-inflammatory effects in Oxa induced murine AD model. Recovery of epidermal permeability barrier function was also accelerated by CB1R-agonist. Hyper-proliferation and abnormal differentiation were attenuated by co-application of CB1R-agonist. Epidermal expression of IL-8 was down-regulated by CB1R-agonist. CB1R is involved in AD pathogenesis and CB1R-agonist might be a therapeutic regiment for AD.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|